Oracle Health Joins G42, Cleveland Clinic in AI Deal
Home » Smart Sectors » Healthcare » Oracle Health Joins G42, Cleveland Clinic in AI Deal
Oracle Health, Cleveland Clinic, and G42 have announced a new strategic partnership. The goal is to develop an AI-based healthcare delivery platform. This platform aims to improve patient care and public health management.
The partners will use artificial intelligence, national-scale data analytics, and intelligent clinical tools. Together, they seek to build secure, scalable, and accessible care models that improve health and longevity.
The platform will serve as the base for an AI-powered healthcare hub. It will integrate Oracle Cloud Infrastructure, Oracle AI Data Platform, and Oracle Health applications. It will also benefit from Cleveland Clinic's clinical expertise and G42's sovereign AI infrastructure.
The partnership targets evolving global healthcare needs. It will start with operations in the United States and the United Arab Emirates. The aim is to deliver secure and intelligent solutions that enhance patient outcomes and enable precision medicine.
The platform will allow a shift from reactive care to proactive wellbeing. Real-time analysis of population and public health data will be enabled. Clinical teams will gain immediate access to insights at the point of care.
Reportedly, the system will help healthcare providers reduce costs while improving care quality. It will support both clinical and operational leaders with predictive tools and decision-making analytics. The platform will support diagnostics, personalized treatments, and cost optimization.
It will provide high-quality, affordable care to address aging populations and chronic illness.
The collaboration will also bridge the gap between clinical care and research. Providers can identify and enroll clinical trial candidates more easily. Researchers will gain access to real-world data for faster development of new treatments.
The new platform is designed to: Prioritize data privacy, clinical quality, and efficiency.
Create scalable, cost-effective care models for the U.S. and UAE.
Oracle Executive Chairman and CTO Larry Ellison said the partnership will reinvent care delivery. He highlighted the role of Oracle's AI Data Platform in driving scientific breakthroughs and reducing healthcare costs.
Cleveland Clinic President and CEO Tom Mihaljevic called the initiative a 'bold leap forward.' He noted the potential of AI-powered care to lower costs, improve outcomes, and expand access.
Peng Xiao, Group CEO at G42, said the project reflects the power of the UAE–US technology corridor. He emphasized its goal to build a new health intelligence model focused on equity and longevity.
This partnership sets a new example of public-private collaboration in healthcare. It demonstrates how AI and data-driven innovation can reshape care delivery.
Cleveland Clinic and G42 already work together through Cleveland Clinic Abu Dhabi. The UAE has also maintained a strong partnership with Cleveland Clinic for decades.
The agreement is currently non-binding.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
3 days ago
- The National
Abu Dhabi's dedicated cancer centre treats 25,000 patients in first two years
A dedicated Abu Dhabi cancer centre has delivered crucial treatment to more than 25,000 patients since opening to the public two years ago under a vision to transform health care in the Emirates. Health leaders at the Fatima bint Mubarak Centre, based at Cleveland Clinic Abu Dhabi, have told of their mission to "lead the future of oncology" from the UAE capital. Patients at the centre, which is modelled on Cleveland Clinic's Taussig Cancer Centre in the US, receive personalised care for in all forms of cancer from individual teams with expertise, comprises oncologists, surgeons, radiologists, radiation therapists, nurses and rehabilitation specialists. 'Gone are the days when a patient needs to go from place to place, everything they need is here,' said Dr Stephen Grobmyer, head of the Fatima bint Mubarak Cancer Centre, which opened in March 2023. Don't delay in seeking support But doctors say the public must also play their part to win the fight against cancer, by ensuring they do not delay in going for check-ups. 'We need people to understand that a delay in diagnosis is often a missed opportunity,' said Dr Fady Geara, chairman of radiation oncology. 'We are seeing patients who wait weeks or months before seeking help and, by the time they arrive, their window for a cure may already be closing.' The critical need for early intervention was highlighted in recent research, which indicated a 60 per cent rise in newly diagnosed cases between 2019 an 2023. The series paper, titled Cancer Control in the United Arab Emirates, co-written by leading UAE-based oncologists and global experts, called for an urgent and comprehensive national strategy to address rising cases, inequities in care and preventive services not being used enough. 'We're urging people to get screened, especially those with family histories or known risk factors,' Dr Geara said. 'The hardship of travelling abroad for care is no longer necessary. World-class treatment is available right here.' World-class care Dr Usman Ahmad, chairman of thoracic surgery, who leads the institute's robotic and minimally invasive surgery programme, agreed patients no longer having to travel abroad for treatment was a huge advantage. 'Robotic surgery allows us to operate through small keyhole incisions with exceptional precision and safety," he added. "The result is less pain, fewer complications and much faster recovery times.' The programme includes surgery for lung, oesophageal, stomach, prostate, kidney, bladder and gynaecological cancer. 'Our patients start walking the same day or the next, go home in a few days and recover fast enough to begin follow-up therapies such as chemotherapy or immunotherapy without delay,' said Dr Ahmad. Radiation oncology has also undergone major advancements under Dr Geara. 'We've brought in the most advanced technologies, including adaptive radiation therapy, brachytherapy and radio surgery,' he said. 'These methods reduce treatment sessions while improving cure rates and they're all now available right here in the UAE.' Brachytherapy, which involves using radiation directly on or near a tumour, is rarely found even in some major hospitals abroad. It is now carried out daily at the centre. Dr Geara said the institute had also begun work on a dedicated heavy ion therapy complex, a carbon-ion therapy considered among the most advanced in the world, capable of targeting tumours that cannot be treated through conventional means. Construction of the heavy ion centre is expected to take two to three years. Cleveland Clinic Abu Dhabi's cancer programme extends far beyond treatment. Under the leadership of Dr Fawad Khan, the longevity medicine section has introduced a pioneering preventive care programme for cancer survivors and those at high genetic risk of developing the disease. This includes comprehensive genetic screening, counselling and prevention strategies, from enhanced screening and medication to preventive surgery. The longevity medicine team comprises lifestyle physicians, physical therapists, genetic counsellors, naturopaths and psychologists. A major element of the programme is its use of precision genomics. 'We're conducting germ line, somatic and pharmacogenomic testing to guide treatment, prevent cancer and minimise side effects,' said Dr Khan. They collaborate closely with the Emirati Genome Programme and M42, allowing access to data crucial to bolstering care and mitigating health risks. One study now under way involves the use of polygenic risk scores to better identify breast cancer risks in Emirati women. 'This research has largely focused on western populations,' Dr Khan said. 'By focusing on Arab populations, we can greatly improve regional outcomes and design tailored prevention programmes.' Clinical trials are another growing sector. 'Trials are how new treatments come into the world,' said Dr Grobmyer. 'It's no longer enough to assume treatments tested abroad will work here. We need to prove they do with local data and regional representation.' A newly launched programme uses wearable BioButton sensors to track vital signs in real time once a patient leaves the hospital. Nurses can detect early signs of infection, dehydration, or other complications and intervene before symptoms worsen. 'The technology allows us to call patients before they call us,' said Dr Grobmyer. 'In many cases, we've been able to prevent hospital readmissions entirely.' He said the programme is already being used in chemotherapy patients and is expected to expand across surgical units. Long-term strategy The institute is also preparing the next generation of physicians. Next year, it will launch a four-year residency in oncology, accredited by the UAE board. Preference will be given to Emirati candidates, with the goal of building a sustainable domestic workforce in cancer care. 'Our long-term goal is not just to be takers of global excellence but contributors to it,' said Dr Grobmyer. 'Through clinical research, genomics, AI and training, we want to lead the future of oncology here in Abu Dhabi and around the world.'
Khaleej Times
4 days ago
- Khaleej Times
Inside UAE's most advanced cancer centre: Wearables, robotic surgery, carbon-ion therapy
From real-time patient monitoring and robotic surgery to genomic screening and heavy-ion therapy, Cleveland Clinic Abu Dhabi's Fatima bint Mubarak Center is progressing how cancer is diagnosed, treated, and prevented in the UAE. Marking its second anniversary, the centre's leadership presented a series of updates that reflect the growing scale and sophistication of the country's cancer care infrastructure. "We've treated over 27,000 cancer patients since inception," said Dr Stephen Grobmyer, Chief of the Cancer Institute. "But what's more exciting is where we're going." Wearables and cooling devices Among the most immediate changes affecting patients today is the roll-out of the BioButton, a medical-grade wearable that remotely tracks a patient's vital signs after chemotherapy or surgery. "We're putting it on almost all patients who start on chemotherapy," Dr Grobmyer confirmed, adding that it allows clinicians to identify signs of deterioration early and proactively intervene. "We can detect early warning signs like increased temperature or heart rate before the patient even notices. One of our patients, for example, was starting to experience complications like nausea and vomiting. We contacted them before it escalated, brought them in for fluids, and they were able to return home without hospital admission." The centre is also investing in supportive technologies to preserve the quality of life during treatment. Cooling caps, used to reduce chemotherapy-related hair loss, have already shown tangible results. "I had a patient last week who finished chemotherapy and still had almost all of her hair. She was very happy about that," said Dr Grobmyer. For patients facing neuropathy, a side effect of some cancer medications, cooling gloves are being used to reduce nerve damage in hands and feet. Robotic surgery = smaller cuts, faster recovery Dr Usman Ahmad, division chair of Thoracic Surgery, Heart, Vascular and Thoracic Institute, explained how Cleveland Clinic Abu Dhabi has made robotic and minimally invasive surgery the new norm for cancer patients across specialities. "There is no surgical treatment for which the patients have to leave the UAE now," he said. He emphasised the dramatic improvement in recovery times through robotic surgery. "Instead of big incisions, we operate through keyholes. Patients start walking the same day or the next, go home in a few days, and can start further treatment like chemotherapy or immunotherapy within a week or two." He described the shift from older surgical methods in vivid terms: "The robotic technology is so advanced that the instruments act like my hands inside the patient's body, without me having to put my hands inside. Traditional thoracic surgery might require an incision this big," he said, gesturing from his heart to the abdomen area. "Now, we do the entire operation through incisions the size of a fingertip." Dr Ahmad noted that nearly all types of cancer surgeries, including for lung, stomach, oesophagus, kidney, prostate, and ovarian cancers, are now performed robotically. "We don't compromise on safety or quality. These are the same standards you'd find in the US or Europe." AI, adaptive radiation and heavy ion therapy Radiation oncology has also seen a leap forward, with Cleveland Clinic Abu Dhabi now offering AI-powered adaptive radiation and brachytherapy, internal radiation delivered directly to the tumour. "Adaptive radiation is among the most advanced in the world," said Dr Fady Geara, Division Chair of Radiation Oncology. "We adjust the radiation in real-time during treatment to follow the tumour's exact position and spare healthy tissue." He added that this is especially useful for abdominal and pelvic cancers, where organs shift frequently. The centre's brachytherapy programme is now operating daily and, according to Dr Geara, is often "not even available in many US centres." As previously announced, the facility is preparing to launch the region's first carbon-ion therapy centre - a treatment for tumours resistant to traditional methods. "We're building a new facility to house the synchrotron accelerator," said Dr Geara. "We aim to treat our first patient in two to three years, or possibly sooner." Genomics, prevention, and regional leadership A polygenic risk score (PRS) study to predict breast cancer in patients without known genetic mutations is also underway. "Most global data is from Western populations," said Dr Fawad Khan, Staff Physician for Longevity Medicine. "We're now validating this in Emiratis, which will also benefit the wider Arab population." The hospital's longevity and high-risk prevention programmes already serve hundreds of patients, both survivors and those with elevated risk, including international patients from Saudi Arabia and Qatar. "This is not a branch of Cleveland Clinic," Dr. Grobmyer emphasised. "We are Cleveland Clinic. Our tumour boards include our colleagues in Ohio, and our goal is not just to take from the system but to contribute new knowledge back." Training the next generation As part of that long-term vision, the centre has received approval to launch a four-year oncology residency programme starting in 2026. "Our preference is to train locals - Emirati doctors, but we also bring in candidates from the wider region when needed," said Dr Grobmyer. He noted that the programme, accredited through the UAE's board system, is designed to match the standards of top US fellowships. "It's a long journey," he added, describing the structure as a progression from internal medicine training to subspecialty practice in solid tumour oncology and malignant haematology. Once trainees complete the full programme and pass board exams, "they will be independently able to manage the full spectrum of diseases," he explained, Dr Ahmad stressed how early detection saves lives, and no one in the UAE needs to leave the country for treatment as they could receive timely, high-quality, sufficient treatment in the capital. "While our technology is world-class, it's only useful if people get to us in time," he concluded.
Zawya
4 days ago
- Zawya
G42, Liquid AI partner to deliver efficient AI solutions to enterprises
ABU DHABI: G42, the Abu Dhabi-based global technology group, and Liquid AI, a leading efficient foundation models company headquartered in Cambridge, Massachusetts, today announced that they have entered into a multifaceted commercial partnership to facilitate the creation, training and commercialisation of generative AI solutions powered by Liquid Foundation Models. The goal of the partnership is to jointly develop and deploy private generative AI solutions internationally, from the Middle East and North Africa to the Global South, and across many sectors, such as investment and banking, consumer electronics, telecommunications, biotech, and energy. G42 companies such as Core42 and Inception are involved in various aspects of the partnership, from AI infrastructure for AI development to co-designing multimodal foundation models and deployment. 'This partnership reflects our shared vision for AI that is sovereign, efficient, and enterprise-ready,' said Dr. Andrew Jackson, group chief AI officer of G42. 'By combining G42's infrastructure with Liquid AI's model innovation, we're advancing scalable, trusted AI solutions for global industries.' 'The scale and impact that G42 has brought to the AI world is inspiring,' said Ramin Hasani, co-founder and CEO of Liquid AI. 'This partnership, complementary to the global AI momentum, enables a top-down approach to delivering efficient, capable, and private general-purpose AI models at scale to enterprises faster than ever.' In light of the recent US-UAE AI acceleration partnership, this alliance is another testament to the commitment of both initiatives to building responsible and inclusive AI for all.
